Q-omics provides the consensus-scored ZNF92 profile across patient tissues and cancer cell-line models. ZNF92 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZNF92 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, ZNF92 RNA expression shows 21,183 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, BLCA, and ACC as cancer lineages where ZNF92 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF92 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF92 survival associations across molecular data types. ZNF92 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF92 RNA expression–survival associations across cancer types. High ZNF92 expression shows unfavorable associations in CESC, ACC, UVM and LIHC, but favorable associations in UCS and BRCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ZNF92 RNA expression.
This table summarizes ZNF92 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF92. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF92 shows lower tumor expression in THCA and higher tumor expression in BLCA, KIRP, LUAD, LIHC and STAD. The BLCA box plot shows higher ZNF92 RNA expression in tumor versus normal tissue (log2 FC = +1.692, t-test p < 0.001).
This table shows molecular features associated with ZNF92 in patient tissues and cancer cell lines. In patient samples, ZNF92 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF92 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
